Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy

Immunostimulatory monoclonal antibodies (mAbs) exert antineoplastic effects by eliciting a novel or reinstating a pre-existing antitumor immune response. Most often, immunostimulatory mAbs activate T lymphocytes or natural killer (NK) cells by inhibiting immunosuppressive receptors, such as cytotoxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aranda, Fernando, Vacchelli, Erika, Eggermont, Alexander, Galon, Jerome, Fridman, Wolf Hervé, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961485/
https://www.ncbi.nlm.nih.gov/pubmed/24701370
http://dx.doi.org/10.4161/onci.27297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961485/
https://www.ncbi.nlm.nih.gov/pubmed/24701370
http://dx.doi.org/10.4161/onci.27297

Ejemplares similares